Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study.

Clémence BlaizeEllina SurtouqueJonaz Font Charles DolladilleSophie Postel-VinayAngélique Da SilvaJoachim AlexandrePierre-Marie Morice

Published in: Fundamental & clinical pharmacology (2024)

In a context of extensive assessment of niraparib in combination, these data reinforce the need of a close monitoring of this adverse event to preserve its clinical benefit on patients' survival.

Keyphrases

arterial hypertension
end stage renal disease
randomized controlled trial
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
adverse drug
emergency department
machine learning
big data
deep learning
double blind